Valeant Bondholders Eyeing Value After Plunge on Drug AccountingBy
Bond investors say rising cashflow supports debt prices
Some holders see buying opportunity after yields surged
Bond investors are starting to see value in embattled Valeant Pharmaceuticals International Inc. after heightened scrutiny of its business and accounting practices sent its stock and debt prices tumbling.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.